These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

500 related items for PubMed ID: 11331087

  • 1. Allopregnanolone levels and reactivity to mental stress in premenstrual dysphoric disorder.
    Girdler SS, Straneva PA, Light KC, Pedersen CA, Morrow AL.
    Biol Psychiatry; 2001 May 01; 49(9):788-97. PubMed ID: 11331087
    [Abstract] [Full Text] [Related]

  • 2. Allopregnanolone serum concentrations and diurnal cortisol secretion in women with premenstrual dysphoric disorder.
    Segebladh B, Bannbers E, Moby L, Nyberg S, Bixo M, Bäckström T, Sundström Poromaa I.
    Arch Womens Ment Health; 2013 Apr 01; 16(2):131-7. PubMed ID: 23329007
    [Abstract] [Full Text] [Related]

  • 3. Stress, mood, and cortisol during daily life in women with Premenstrual Dysphoric Disorder (PMDD).
    Beddig T, Reinhard I, Kuehner C.
    Psychoneuroendocrinology; 2019 Nov 01; 109():104372. PubMed ID: 31357135
    [Abstract] [Full Text] [Related]

  • 4. 5α-Reductase Inhibition Prevents the Luteal Phase Increase in Plasma Allopregnanolone Levels and Mitigates Symptoms in Women with Premenstrual Dysphoric Disorder.
    Martinez PE, Rubinow DR, Nieman LK, Koziol DE, Morrow AL, Schiller CE, Cintron D, Thompson KD, Khine KK, Schmidt PJ.
    Neuropsychopharmacology; 2016 Mar 01; 41(4):1093-102. PubMed ID: 26272051
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. GABAergic neuroactive steroid response to sertraline in premenstrual dysphoric disorder.
    Miller KN, Standeven L, Morrow AL, Payne JL, Epperson CN, Hantsoo L.
    Psychoneuroendocrinology; 2024 Feb 01; 160():106684. PubMed ID: 38091917
    [Abstract] [Full Text] [Related]

  • 13. Changes in mood, cognitive performance and appetite in the late luteal and follicular phases of the menstrual cycle in women with and without PMDD (premenstrual dysphoric disorder).
    Reed SC, Levin FR, Evans SM.
    Horm Behav; 2008 Jun 01; 54(1):185-93. PubMed ID: 18413151
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Estrogen, progesterone, cortisol, brain-derived neurotrophic factor, and vascular endothelial growth factor during the luteal phase of the menstrual cycle in women with premenstrual dysphoric disorder.
    Ko CH, Wong TH, Suen JL, Lin PC, Long CY, Yen JY.
    J Psychiatr Res; 2024 Jan 01; 169():307-317. PubMed ID: 38070471
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Association between Generalized Anxiety Disorder and Premenstrual Dysphoric Disorder in a Diagnostic Interviewing Study.
    Yen JY, Lin PC, Huang MF, Chou WP, Long CY, Ko CH.
    Int J Environ Res Public Health; 2020 Feb 05; 17(3):. PubMed ID: 32033286
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Allopregnanolone and mood disorders.
    Bäckström T, Bixo M, Johansson M, Nyberg S, Ossewaarde L, Ragagnin G, Savic I, Strömberg J, Timby E, van Broekhoven F, van Wingen G.
    Prog Neurobiol; 2014 Feb 05; 113():88-94. PubMed ID: 23978486
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.